369 results on '"Dacic, S"'
Search Results
2. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center
3. PL03.07 Invasion or No Invasion, That’s the Question. A Large Reproducibility Study in Pulmonary Adenocarcinoma, Supporting a Modified Classification
4. P1.12-08 Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC)
5. PP01.39 Infrastructure for Interobserver Variability Assessment of Pathologic Response (PR), in Surgical Resection Specimens Following Neoadjuvant Immune Check Point Inhibitor (ICI) Therapies in Early Stage NSCLC
6. PP01.53 Pathologic Response Assessment Tool – Architecting a Cloud-Based Tool to Streamline Logistics for Shipping, Tracking, Scoring, and Reporting
7. A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer
8. MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population
9. EP11.02-002 A Comparative Study of PD-L1 Scoring: Humans versus AI
10. P1.06-01 Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III Study
11. MA12.07 Defining Morphologic Features of Invasion in Pulmonarynon-Mucinousadenocarcinoma with Lepidic Growth
12. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
13. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15
14. Tumours of the lung : introduction
15. EP13.04-02 Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up
16. Neoadjuvantes Osimertinib mit/ohne Chemotherapie vs.Chemotherapie bei EGFR-mutiertem resektablem NSCLC: NeoADAURA
17. ES17.04 Updates in Mesothelioma
18. P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
19. Genotypic analysis of pulmonary Langerhans cell histiocytosis
20. ES12.01 Multiple Lung Nodules
21. P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer
22. Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients
23. MTE02.01 Update on WHO Classification and Staging of Lung Cancer
24. OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study
25. Time is up for PD-L1 testing standardization in lung cancer
26. Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study
27. P2.02-047 Comparison of PD-L1 Immunohistochemistry Assays and Response to PD-L1 Inhibitors
28. Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients
29. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma
30. Enrichment of Met Amplification and Kras Mutations in Non-Small Cell Lung Carcinoma (NSCLC) Brain Metastases
31. Prediction of NSCLC Survival With the PAM50 Breast Cancer Signature
32. The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis
33. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15
34. PATHOLOGY
35. Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).
36. 434 Aspergillus-Specific Immunohistochemistry and In Situ Hybridization Facilitate Diagnosis of Aspergillosis
37. 649: Survival of Lung Transplant Recipients with Incidental Finding of Cancer in the Explanted Lung(s)
38. In vitro analysis of clastogenic effects of adrenaline on human lymphocytes
39. The effects of BPC on various models of gastroduodenal lesions in comparison with different agents
40. PD-020 Correlation between epidermal growth factor receptor (EGFR) protein expression (PE) and gene amplification (GA) in non-small cell lung carcinoma (NSCLC)
41. Correlation between epidermal growth factor receptor (EGFR) protein expression (PE) and gene amplification (GA) in non-small cell lung carcinoma (NSCLC)
42. Col1a1-Driven Transgenic Markers of Osteoblast Lineage Progression
43. Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients
44. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.
45. Software environment for complex machine programming.
46. Pulmonary preneoplasia.
47. Postoperative Fluorescence Bronchoscopic Surveillance in Non-Small Cell Lung Cancer Patients
48. Subdividing NSCLC: reflections on the past, present, and future of lung cancer therapy.
49. Regional changes in ectonucleotidase activity after cortical stab injury in rat
50. TEMPORAL AND CELLULAR EXPRESSION PATTERN OF LC AND N TYPE OF VOLTAGE-DEPENDENT CALCIUM CHANNELS AFTER CORTICAL INJURY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.